Search for author "A. Michael Lincoff"
141 Results
- Open AccessSafety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial InfarctionClinical PerspectiveThe AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I)C. Michael Gibson, Serge Korjian, Pierluigi Tricoci, Yazan Daaboul, Megan Yee, Purva Jain, John H. Alexander, P. Gabriel Steg, A. Michael Lincoff, John J.P. Kastelein, Roxana Mehran, Denise M. D’Andrea, Lawrence I. Deckelbaum, Bela Merkely, Maciej Zarebinski, Ton Oude Ophuis and Robert A. HarringtonCirculation. 2016;134:1918-1930, originally published November 15, 2016https://doi.org/10.1161/CIRCULATIONAHA.116.025687
- Table 1.Open AccessSafety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial InfarctionClinical PerspectiveC. Michael Gibson, Serge Korjian, Pierluigi Tricoci, Yazan Daaboul, Megan Yee, Purva Jain, John H. Alexander, P. Gabriel Steg, A. Michael Lincoff, John J.P. Kastelein, Roxana Mehran, Denise M. D’Andrea, Lawrence I. Deckelbaum, Bela Merkely, Maciej Zarebinski, Ton Oude Ophuis, Robert A. HarringtonCirculation December 2016, 134 (24) 1918-1930; DOI: https://doi.org/10.1161/CIRCULATIONAHA.116.025687By C. Michael Gibson, Serge Korjian, Pierluigi Tricoci, Yazan Daaboul, Megan Yee, Purva Jain, John H. Alexander, P. Gabriel Steg, A. Michael Lincoff, John J.P. Kastelein, Roxana Mehran, Denise M. D’Andrea, Lawrence I. Deckelbaum, Bela Merkely, Maciej Zarebinski, Ton Oude Ophuis and Robert A. Harrington
- Figure 1.Open AccessSafety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial InfarctionClinical PerspectiveC. Michael Gibson, Serge Korjian, Pierluigi Tricoci, Yazan Daaboul, Megan Yee, Purva Jain, John H. Alexander, P. Gabriel Steg, A. Michael Lincoff, John J.P. Kastelein, Roxana Mehran, Denise M. D’Andrea, Lawrence I. Deckelbaum, Bela Merkely, Maciej Zarebinski, Ton Oude Ophuis, Robert A. HarringtonCirculation December 2016, 134 (24) 1918-1930; DOI: https://doi.org/10.1161/CIRCULATIONAHA.116.025687By C. Michael Gibson, Serge Korjian, Pierluigi Tricoci, Yazan Daaboul, Megan Yee, Purva Jain, John H. Alexander, P. Gabriel Steg, A. Michael Lincoff, John J.P. Kastelein, Roxana Mehran, Denise M. D’Andrea, Lawrence I. Deckelbaum, Bela Merkely, Maciej Zarebinski, Ton Oude Ophuis and Robert A. Harrington
- Table 2.Open AccessSafety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial InfarctionClinical PerspectiveC. Michael Gibson, Serge Korjian, Pierluigi Tricoci, Yazan Daaboul, Megan Yee, Purva Jain, John H. Alexander, P. Gabriel Steg, A. Michael Lincoff, John J.P. Kastelein, Roxana Mehran, Denise M. D’Andrea, Lawrence I. Deckelbaum, Bela Merkely, Maciej Zarebinski, Ton Oude Ophuis, Robert A. HarringtonCirculation December 2016, 134 (24) 1918-1930; DOI: https://doi.org/10.1161/CIRCULATIONAHA.116.025687By C. Michael Gibson, Serge Korjian, Pierluigi Tricoci, Yazan Daaboul, Megan Yee, Purva Jain, John H. Alexander, P. Gabriel Steg, A. Michael Lincoff, John J.P. Kastelein, Roxana Mehran, Denise M. D’Andrea, Lawrence I. Deckelbaum, Bela Merkely, Maciej Zarebinski, Ton Oude Ophuis and Robert A. Harrington
- Table 3.Open AccessSafety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial InfarctionClinical PerspectiveC. Michael Gibson, Serge Korjian, Pierluigi Tricoci, Yazan Daaboul, Megan Yee, Purva Jain, John H. Alexander, P. Gabriel Steg, A. Michael Lincoff, John J.P. Kastelein, Roxana Mehran, Denise M. D’Andrea, Lawrence I. Deckelbaum, Bela Merkely, Maciej Zarebinski, Ton Oude Ophuis, Robert A. HarringtonCirculation December 2016, 134 (24) 1918-1930; DOI: https://doi.org/10.1161/CIRCULATIONAHA.116.025687By C. Michael Gibson, Serge Korjian, Pierluigi Tricoci, Yazan Daaboul, Megan Yee, Purva Jain, John H. Alexander, P. Gabriel Steg, A. Michael Lincoff, John J.P. Kastelein, Roxana Mehran, Denise M. D’Andrea, Lawrence I. Deckelbaum, Bela Merkely, Maciej Zarebinski, Ton Oude Ophuis and Robert A. Harrington
- Figure 2.Open AccessSafety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial InfarctionClinical PerspectiveC. Michael Gibson, Serge Korjian, Pierluigi Tricoci, Yazan Daaboul, Megan Yee, Purva Jain, John H. Alexander, P. Gabriel Steg, A. Michael Lincoff, John J.P. Kastelein, Roxana Mehran, Denise M. D’Andrea, Lawrence I. Deckelbaum, Bela Merkely, Maciej Zarebinski, Ton Oude Ophuis, Robert A. HarringtonCirculation December 2016, 134 (24) 1918-1930; DOI: https://doi.org/10.1161/CIRCULATIONAHA.116.025687By C. Michael Gibson, Serge Korjian, Pierluigi Tricoci, Yazan Daaboul, Megan Yee, Purva Jain, John H. Alexander, P. Gabriel Steg, A. Michael Lincoff, John J.P. Kastelein, Roxana Mehran, Denise M. D’Andrea, Lawrence I. Deckelbaum, Bela Merkely, Maciej Zarebinski, Ton Oude Ophuis and Robert A. HarringtonTime to occurrence of first major adverse cardiovascular event (MACE). Composite of cardiov...Show MoreTime to occurrence of first major adverse cardiovascular event (MACE). Composite of cardiovascular (CV) death, nonfatal myocardial infarction (MI), ischemic stroke, and hospitalization for unstable angina. HR indicates hazard ratio.Show Less
- Figure 3.Open AccessSafety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial InfarctionClinical PerspectiveC. Michael Gibson, Serge Korjian, Pierluigi Tricoci, Yazan Daaboul, Megan Yee, Purva Jain, John H. Alexander, P. Gabriel Steg, A. Michael Lincoff, John J.P. Kastelein, Roxana Mehran, Denise M. D’Andrea, Lawrence I. Deckelbaum, Bela Merkely, Maciej Zarebinski, Ton Oude Ophuis, Robert A. HarringtonCirculation December 2016, 134 (24) 1918-1930; DOI: https://doi.org/10.1161/CIRCULATIONAHA.116.025687By C. Michael Gibson, Serge Korjian, Pierluigi Tricoci, Yazan Daaboul, Megan Yee, Purva Jain, John H. Alexander, P. Gabriel Steg, A. Michael Lincoff, John J.P. Kastelein, Roxana Mehran, Denise M. D’Andrea, Lawrence I. Deckelbaum, Bela Merkely, Maciej Zarebinski, Ton Oude Ophuis and Robert A. HarringtonTime to occurrence of first exploratory major adverse cardiovascular event (MACE). Composit...Show MoreTime to occurrence of first exploratory major adverse cardiovascular event (MACE). Composite of cardiovascular (CV) death, nonfatal myocardial infarction (MI), and stroke. HR indicates hazard ratio.Show Less
- Table 4.Open AccessSafety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial InfarctionClinical PerspectiveC. Michael Gibson, Serge Korjian, Pierluigi Tricoci, Yazan Daaboul, Megan Yee, Purva Jain, John H. Alexander, P. Gabriel Steg, A. Michael Lincoff, John J.P. Kastelein, Roxana Mehran, Denise M. D’Andrea, Lawrence I. Deckelbaum, Bela Merkely, Maciej Zarebinski, Ton Oude Ophuis, Robert A. HarringtonCirculation December 2016, 134 (24) 1918-1930; DOI: https://doi.org/10.1161/CIRCULATIONAHA.116.025687By C. Michael Gibson, Serge Korjian, Pierluigi Tricoci, Yazan Daaboul, Megan Yee, Purva Jain, John H. Alexander, P. Gabriel Steg, A. Michael Lincoff, John J.P. Kastelein, Roxana Mehran, Denise M. D’Andrea, Lawrence I. Deckelbaum, Bela Merkely, Maciej Zarebinski, Ton Oude Ophuis and Robert A. Harrington
- Table 5.Open AccessSafety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial InfarctionClinical PerspectiveC. Michael Gibson, Serge Korjian, Pierluigi Tricoci, Yazan Daaboul, Megan Yee, Purva Jain, John H. Alexander, P. Gabriel Steg, A. Michael Lincoff, John J.P. Kastelein, Roxana Mehran, Denise M. D’Andrea, Lawrence I. Deckelbaum, Bela Merkely, Maciej Zarebinski, Ton Oude Ophuis, Robert A. HarringtonCirculation December 2016, 134 (24) 1918-1930; DOI: https://doi.org/10.1161/CIRCULATIONAHA.116.025687By C. Michael Gibson, Serge Korjian, Pierluigi Tricoci, Yazan Daaboul, Megan Yee, Purva Jain, John H. Alexander, P. Gabriel Steg, A. Michael Lincoff, John J.P. Kastelein, Roxana Mehran, Denise M. D’Andrea, Lawrence I. Deckelbaum, Bela Merkely, Maciej Zarebinski, Ton Oude Ophuis and Robert A. Harrington
- Table 6.Open AccessSafety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial InfarctionClinical PerspectiveC. Michael Gibson, Serge Korjian, Pierluigi Tricoci, Yazan Daaboul, Megan Yee, Purva Jain, John H. Alexander, P. Gabriel Steg, A. Michael Lincoff, John J.P. Kastelein, Roxana Mehran, Denise M. D’Andrea, Lawrence I. Deckelbaum, Bela Merkely, Maciej Zarebinski, Ton Oude Ophuis, Robert A. HarringtonCirculation December 2016, 134 (24) 1918-1930; DOI: https://doi.org/10.1161/CIRCULATIONAHA.116.025687By C. Michael Gibson, Serge Korjian, Pierluigi Tricoci, Yazan Daaboul, Megan Yee, Purva Jain, John H. Alexander, P. Gabriel Steg, A. Michael Lincoff, John J.P. Kastelein, Roxana Mehran, Denise M. D’Andrea, Lawrence I. Deckelbaum, Bela Merkely, Maciej Zarebinski, Ton Oude Ophuis and Robert A. Harrington
Pages
Journal
Article Type
Article Type
- ACCF/AHA Practice Guideline 58
- ACS: ECG, Angiography, Imaging-Diagnostic, Pathophysiologic, Prognostic Insights 2
- Acute Coronary Syndromes 14
- Acute Coronary Syndromes: Drug Therapies, Bleeding, and Outcomes 1
- Acute Coronary Syndromes: Insights into Risk and Treatment 2
- Advances in Antithrombotic Therapies in Acute Coronary Syndromes 1
- Antithrombin Therapy for ACS 2
- Atherosclerosis, Vascular Biology and Development 1
- Catheter-Based Coronary Interventions: Stent Complications 2
- Catheter-Based Coronary Interventions: Stents: Registry Reports 1
- Catheter-Based Coronary Interventions: Stents: Safety Issues 1
- Catheter-based coronary interventions: stents 7
- Clinical Science 20
- Contemporary STE and NSTE ACS Care 1
- Core 2. Epidemiology and Prevention of CV Disease: Physiology, Pharmacology and Lifestyle 1
- Core 2: Epidemiology and Prevention of CV Disease: Physiology, Pharmacology, and Lifestyle 2
- Core 6. Catheter-based and Surgical Interventions 1
- Core 7. Vascular Disease: Biology and Clinical Science 3
- Coronary Interventions 15
- Coronary Stent Thrombosis 2
- Featured Research: Thrombin Inhibition, Bleeding, and Outcomes in ACS 4
- Intervention and Surgery 1
- Lifestyle Factors 1
- New Drugs and Technologies 8
- Original Article 16
- Original Articles 15
- Original Articles Original Article Original Articles 8
- Original Articles Original Article Original Articles Coronary Interventions 7
- Original Research Article 10
- Percutaneous Coronary Intervention 6
- Poster 4
- Poster Session Title: Poster Session III 2
- Prognosis and Pharmacologic Therapy in ACS 1
- Risk Factor Interventions: Effects and Impact 2
- Secondary prevention 8
- Session Title: ACS and PCI: 30-Day Outcomes and Posthospitalization Care 1
- Session Title: CTOs, Left Mains, Bifurcations and Multivessel Disease 1
- Session Title: Diabetes Mellitus and CVD: Mechanistic Insights 1
- Session Title: HDL and the Artery Wall 1
- Session Title: Myocardial Protection, Intraoperative Management, and Postoperative Critical Care 1
- Session Title: Poster Session III 4
- Session Title: Unstable Angina, NSTEMI and STEMI: Prognosis and Pharmacologic Therapy-Focus on Patient Risk 1
- Session Title: Unstable Angina, NSTEMI and STEMI: Prognosis and Pharmacological Therapy 1
- Session Title: What's New in the Treatment of Patients with Acute Coronary Syndromes? 1
- Type 2 diabetes 7
- Volume 126, Issue 21 Supplement; November 20, 2012 / Abstracts From the American Heart Association 2012 Scientific Sessions and Resuscitation Science Symposium 1
Subject
Subject
- CPR and emergency cardiac care 58
- Catheter-based coronary interventions: stents 15
- Lipids and Cholesterol 10
- Secondary prevention 16
- Type 2 diabetes 23
- Volume 126, Issue 21 Supplement; November 20, 2012 / Abstracts From the American Heart Association 2012 Scientific Sessions and Resuscitation Science Symposium 1
Content Type
Resource Type
- Articles 32
- Tables & Figures 60
- HWTABLE 49


